Investigation of the gut microbiome in patients with head and neck cancer (HNSCC) and analysis of the prognostic potential of response and tolerability of PD-1, PDL-1 immune checkpoint inhibitors in head and neck cancer
Recruiting
- Conditions
- head and neck carcinoma
- Registration Number
- DRKS00032481
- Lead Sponsor
- ehrstuhl für Hals-Nasen-Ohrenheilkunde Universität Witten/Herdecke
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Histologically confirmed head and neck carcinoma for which immune checkpoint inhibitor therapy (PD-1, PD-L1) is planned as part of treatment
Exclusion Criteria
Age under 18, lack of capacity to consent, and lack of patient consent
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response to immunocheckpoint inhibitor (PD-1, PD-L) therapy, occurrence of adverse immunotherapyrelated side effects under immuno-checkpoint inhibitor (PD-1, PD-L) therapy when restaging
- Secondary Outcome Measures
Name Time Method Applicability of cloud-based medical diagnostic software (BiomeOne®) in head and neck cancer.